AgeX Therapeutics (NYSE:AGE) Short Interest Down 2.8% in March

AgeX Therapeutics (NYSE:AGE) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 1,018,865 shares, a decline of 2.8% from the February 28th total of 1,048,300 shares. Currently, 5.3% of the company’s shares are short sold. Based on an average daily volume of 67,232 shares, the days-to-cover ratio is currently 15.2 days.

AGE stock traded up $0.11 during midday trading on Friday, hitting $4.57. The company had a trading volume of 31,890 shares, compared to its average volume of 68,352. AgeX Therapeutics has a 52 week low of $1.13 and a 52 week high of $5.95.

A number of institutional investors and hedge funds have recently bought and sold shares of AGE. BlackRock Inc. purchased a new stake in shares of AgeX Therapeutics in the fourth quarter worth $1,810,000. Defender Capital LLC. purchased a new stake in shares of AgeX Therapeutics in the fourth quarter worth $1,379,000. Prescott General Partners LLC purchased a new stake in shares of AgeX Therapeutics in the fourth quarter worth $554,000. Geode Capital Management LLC purchased a new stake in shares of AgeX Therapeutics during the fourth quarter valued at $366,000. Finally, Northern Trust Corp purchased a new stake in shares of AgeX Therapeutics during the fourth quarter valued at $293,000. Institutional investors and hedge funds own 16.36% of the company’s stock.

TRADEMARK VIOLATION WARNING: “AgeX Therapeutics (NYSE:AGE) Short Interest Down 2.8% in March” was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/agex-therapeutics-age-short-interest-down-2-8-in-march.html.

AgeX Therapeutics Company Profile

AgeX Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues.

Featured Article: Debt-To-Equity Ratio

Receive News & Ratings for AgeX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgeX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.